Clinical trial
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
NCT00498602 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00498602 |
|---|---|
| Title | Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease |
| Official title | Phase Iia, Multicenter, Randomized, Third-party Unblinded, Adjuvant And Placebo-controlled, Multiple Ascending Dose, Safety, Tolerability, And Immunogenicity Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Mild To Moderate Alzheimers Disease |
| Lead sponsor | Pfizer, Industry |
| Collaborators | JANSSEN Alzheimer Immunotherapy Research & Development, LLC Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Biological, Other |
| Interventions | ACC-001 + QS-21, QS-21, Diluent: Phosphate Buffered Saline, ACC-001 |
| Enrollment | 160 |
| Start date | Nov 1, 2007 |
| Primary completion | Feb 1, 2013 |
| Completion | Feb 1, 2013 |
| First posted | Jul 10, 2007 |
| Last update posted | Jan 1, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: